• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines

    KemPharm Receives $10M Milestone for FDA Approval of Azstarys

    Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax

    Syneos, Medable Partner for New Decentralized Capabilities

    CSafe Global Appoints SVP of Technology and Innovation
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Evotec to Build Second Biologics Mfg. Facility in Toulouse

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    TraceLink Introduces Opus Platform

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines

    KemPharm Receives $10M Milestone for FDA Approval of Azstarys

    Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax

    Syneos, Medable Partner for New Decentralized Capabilities

    Valneva’s Inactivated, Adjuvanted COVID-19 Vax Achieves Positive Data
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Unifying Quality Manufacturing to Drive Speed, Collaboration, and Compliance

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Syngene

    Aphena Pharma Solutions

    Alcami

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Alcami

    Aphena Pharma Solutions

    Quotient Sciences

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Bio News & Views

    Biopharm Executives Point to Better CMO Performance

    Better process control and increased adoption of single-use systems played a part in improving downstream manufacturing

    Related CONTENT
    • Lessons Learned: Choosing and Managing a CDMO
    • The Ever-Evolving World of Combination Products
    • Embedding Your Drug Strategy Within a Solid Foundation for Success
    • Sepha Launches Small Batch Contract Packaging Service
    • A Potential “Marriage”
    Eric S. Langer, BioPlan Associates, Inc.10.14.14
    Bioprocessing efficiency continues to improve, finds BioPlan Associates in its newly-released 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production.1 Results suggest that biomanufacturers are prioritizing manufacturing efficiency and using a number of different ways to boost productivity.

    This year, we asked global respondents to identify the single most important trend or operational area that the industry must focus on. By a clear margin, the priority was “a greater focus on manufacturing efficiency and productivity.” One in five respondents cited this as the single most important trend of the year, ahead of others such as biosimilars/biogenerics (14%), the implementation and integration of single-use systems (11%) and manufacturing cost reductions (10%). The industry believes that manufacturers and their suppliers need to increase their efforts to produce more, do it more quickly, and do so with fewer resources.

    Improving Biomanufacturing Performance
    With the emphasis on efficiency and productivity, we examined the factors contributing to performance improvements.  Grouped at the top are two leading factors: “Overall better control of processes,” cited by 73% of respondents as creating improvements; and “Use of disposable / single use devices,” cited by 72%. Roughly 6 in 10 respondents also attribute improvements to optimized cell culture processes, and better process development, with improved upstream (59%) and downstream (57%) operations also in the mix.

    We analyzed the changes during recent years in the factors that are credited with improving biomanufacturing performance. Some of the areas where we found significantly more respondents this year include:
    • “Overall better control of process”: 73% this year, vs 71% in 2013
    • “Use of disposable bags / single use devices”: cited by 72%, up from around 67% during the prior 4 years
    • “Better Design of Experiments (DoE), in process development:” 55%, up from 51% last year; and
    • “Better operations staff training”: cited by 53%, up from 49% last year.
    These areas showed appreciable increases; all other factors surveyed were cited by fewer respondents than last year or years prior. Apparently, the increased attention and investments being made in bioprocessing operations are having an impact. But it is significant that of the 15 factors identified, at least one-third of respondents reported improvements in all but one. This further confirms that bioprocessing, including its diverse processes and associated services, continues to improve.

    Gains attributed to better control of process and up- and downstream bioprocessing could be the result of increasing budgets. In last year’s study, survey respondents indicated that they would be increasing their process development budgets by an average of 5.5%, the largest percentage increase of any area measured. 2 Not far behind were planned spending increases on new technologies to improve efficiencies and costs for both upstream and downstream production (4.9% each).

    Although budget expectations this year have tampered down slightly, these areas are still seeing planned increases, with process development (4.4%) and upstream (4.2%) and downstream (4%) production operations at or near the top of respondents’ budget plans.

    For CMOs, Disposable Applications Are Most Beneficial
    We evaluated the differences in how biotherapeutic developers and CMOs perceived key performance factors. In almost each instance, CMOs were more likely to report performance improvements than biotherapeutic developers.  Indeed, of the 15 areas identified, biotherapeutic developers were more likely to see improvements from only 2: Improved upstream production operations (59% crediting with “significant” or “some” improvements, compared to 56% of CMOs); and more automated control of processes (45% vs. 33%, respectively).

    For their part, CMOs were especially more likely to attribute improvements to: 
    • Use of disposable/single-use devices (83% vs. 71%);
    • Improved downstream production operations (72% vs. 55%); and
    • Better Design of Experiements (DoE), related to process development  (72% vs. 53%).
    In fact, use of single-use devices was the area credited by the most CMOs with improving biomanufacturing performance.  

    Improving Downstream, the Persistent Bottleneck
    CMOs’ use of disposable applications to improve productivity also ties in with their improved downstream production operations. Our annual survey continues to show downstream processing being the primary remaining bioprocessing bottleneck; companies are working in different ways to de-bottleneck this issue. And perhaps not too surprisingly, CMOs are more likely than biotherapeutic developers to be turning to single-use devices to improve their downstream operations.

    To identify which activities the industry is undertaking to address downstream bottlenecks, we asked participants about specific technologies and actions their facility has actually implemented to improve those operations. We found that for nearly every implementation factor, CMOs report higher levels of adoption. This is a reflection of CMOs’ dependence on efficiency, along with their higher turnover of multiple products and ability to pass on technology implementation costs to clients.

    In an effort to predict growth in new technologies, we look to where differences between CMOs and biotherapeutic developers are largest, and to consider those few areas where developers are in front in terms of adoption.

    The survey data shows that biotherapeutic developers outstripped CMOs in their investments in downstream process development (36% vs. 18%) and in investigating alternatives to Protein A (33% vs. 18%). But while developers were more likely to investigate Protein A alternatives, it was CMOs who were far more likely to report having switched to alternatives (18% vs. 5%).

    Other similarly large discrepancies in adoption favoring CMOs include:
    Cycling columns more frequently (72.7% of CMOs vs. 54.1% of biotherapeutic developers); Using or evaluating alternative ion exchange technologies (72.7% vs. 47.5%).

    The results suggest that CMOs, by the nature of their profession, are using many different techniques to minimize bottlenecks and maximize capacity from their facilities. In this sense, CMOs more resemble the clinical facilities of product developers which must, by design, be more flexible to handle a diversity of processes. The data also shows that for CMOs, use of disposable applications is being credited with downstream processing improvements, which in turn are leading to overall biomanufacturing performance improvements.

    Despite those improvements, downstream processing continues to rile both CMOs and biomanufacturers. This year, respondents were again asked to describe the impact their downstream purification processes were having on their overall capacity. We found that 69% of respondents (vs. 76% last year, 72% in 2012, and 69% in 2011) reported at least some degree of capacity bottleneck at their facility as a result of downstream processes.

    In fact, the impact of downstream bottlenecks may be on the rise. We found a year-over-year increase in both the proportion of respondents experiencing “serious bottlenecks today” (8% vs. 7%) and “some bottleneck problems” (37% vs. 29%). By contrast, the percentage expecting “no bottlenecks” remained relatively flat at 23%. Downstream issues and production constraints appear to be a chronic complaint.

    The percentage of CMOs and biodevelopers reporting “serious” or “some” capacity problems due to downstream processing both increased from last year. While no CMOs reported “serious” bottlenecks today, 6 in 10 claimed to have had “some,” the highest level since our 2009 study.

    CMOs’ experiences are often harbingers of what’s to come. If this year’s large increase in downstream-blamed bottlenecks is indeed a leading indicator in bioprocessing efficiency, this suggests a trend that downstream problems will be further increasing for developers too. In the context of CMOs having to work with many more products, it would not be surprising if they reported higher downstream bottlenecks and concerns. But it is the nature of CMO business not to assume tasks for which they lack needed resources.

    It seems clear that CMOs are taking the lead in evaluating new technologies. Our study separately found that CMOs were considering a range of new downstream processing solutions at a greater rate than their biotherapeutic developer counterparts. Those include a host of disposable applications, including various single-use filters, disposable UF systems and single-use prepacked columns. Similarly, when we surveyed new product development areas of interest, CMOs were more vocal in their interest in the majority of areas, with disposable purification in particular emerging as one of their key interests, indicated to be among their Top-Five by a majority of CMO respondents. So while CMOs reported more widespread capacity bottlenecks than biotherapeutic developers this year, CMOs are actively searching for and trialing new technologies with the potential to improve productivity. 

    What’s Next in Bioprocessing Efficiency
    The industry is maturing and now finds itself acutely aware of the need for new technologies to optimize, and in some cases revolutionize existing processes. Yet, while end-users still actively look for new technologies to solve persistent problems, these changes are underpinned by very specific needs. Approaches that shorten the time to get facilities up and running and reduce capital investments are mandatory for new facility design. Similarly, the industry is demanding better downstream processes—demands that generally focus on cheaper and more effective chromatography and purification steps.

    The biopharmaceutical industry—and CMOs in particular—are continuing to invest in improved manufacturing methods, particularly concerning process control and optimization. Surprisingly, responses to these questions varied between product manufacturers and CMOs, with the former reporting more frequent implementation of process-related improvements. One might expect CMOs, with their high project turnover and need to do it right quickly and the first time, to be out in front of product manufacturers in terms of implementing process improvements. But many CMOs prefer to standardize their bioprocessing, and many follow the regulatory and manufacturing-related requirements of their clients.

    CMOs are leading the way in disposables adoption, though, and appear to be satisfied with the results, crediting their disposables use with significant improvements in downstream processing and overall biomanufacturing performance. As single-use applications continue to penetrate biopharmaceutical manufacturing and the market for these applications mature, a number of trends can be expected:
    • More quality will be built into single-use systems to attempt to further reduce regulatory activities and oversight;
    • More single-use downstream operations will include membrane adsorbers;
    • Better standards for leachables and extractables testing will emerge; and
    • Problems surrounding disposable devices that are creating inconsistent growth due to changes in resins and cell line specificity, among others, will be addressed.
    One can reasonably expect CMOs to continue at the forefront, pushing these changes—and benefiting from them. 

    References
    1. 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production:  A Survey of Biotherapeutic Developers and Contract Manufacturing Organizations, BioPlan Associates, April 2014. www.bioplanassociates.com/11th

    Eric S. Langer
    BioPlan Associates, Inc.

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports.  elanger@bioplanassociates.com  301-921-5979.  www.bioplanassociates.com
    Related Searches
    • facility
    • quality
    • Biomanufacturing
    • training
    Suggested For You
    Lessons Learned: Choosing and Managing a CDMO Lessons Learned: Choosing and Managing a CDMO
    The Ever-Evolving World of Combination Products The Ever-Evolving World of Combination Products
    Embedding Your Drug Strategy Within a Solid Foundation for Success Embedding Your Drug Strategy Within a Solid Foundation for Success
    Sepha Launches Small Batch Contract Packaging Service Sepha Launches Small Batch Contract Packaging Service
    A Potential “Marriage” A Potential “Marriage”
    Injectables Firms Expand Capacity Injectables Firms Expand Capacity
    TFF Expands Engagement with Experic TFF Expands Engagement with Experic
    India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines
    The Pandemic’s Become an Insurmountable Opportunity The Pandemic’s Become an Insurmountable Opportunity
    Vetio Animal Health Vetio Animal Health
    Current Trends in Analytical Testing Current Trends in Analytical Testing
    CMOs & Biosimilars Mfg. in the U.S. CMOs & Biosimilars Mfg. in the U.S.
    PBOA Praises Action On FDA Reauthorization  PBOA Praises Action On FDA Reauthorization
    Adents, Microsoft Present Serialization Solution Adents, Microsoft Present Serialization Solution
    CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges

    Related Bio News & Views

    • Biosimilars | Logistics | Supply Chain | Validation

      Outsourcing Media and Buffer Prep

      Facilities are evaluating ways to reduce bottlenecks, lower risks, eliminate logistics and inventory costs
      Eric S. Langer, BioPlan Associates, Inc. 09.08.14

    • Biosimilars | Clinical Trials | Drug Delivery | Fill/Finish

      Alvotech and Finesse Enter Bio-Manufacturing Pact

      Catalent, CiRA in regenerative therapy pact
      04.03.14

    • Biosimilars | cGMP Manufacture | Toxicology

      Too Much CMO Capacity?

      ...
      Eric A. Langer, BioPlan Associates 03.07.14


    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development

      CMOs Demanding More Innovations

      Chromatography and single-use equipment top list
      Eric Langer , BioPlan Associates 11.13.13

    • Biosimilars | Validation
      Bio-CMO Capacity Constraints

      Bio-CMO Capacity Constraints

      What they’re doing about them
      Eric Langer, BioPlan Associates 09.05.13

    Trending
    • Franco Negron Named CEO Of ApiJect Systems America
    • Obituary Notice: Russell “Russ” Haines
    • Resilience Acquires Ology Bioservices
    • Johnson & Johnson 1Q Results
    • RDIF, Hualan Ink COVID-19 Vaccine Deal
    Breaking News
    • Nanoform, Aprecia Partner to Advance 3DP Nanomedicines
    • KemPharm Receives $10M Milestone for FDA Approval of Azstarys
    • Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax
    • Syneos, Medable Partner for New Decentralized Capabilities
    • CSafe Global Appoints SVP of Technology and Innovation
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Ashland Supports the Nature Conservancy Forest Restoration Effort to Help Plant a Billion Trees
    Martin Bauer Announces Installation of Agile Filling System at Bethlehem, PA Facility
    PepsiCo and Ingredion Begin Pilot Partnership with Soil and Water Outcomes Fund
    Coatings World

    Latest Breaking News From Coatings World

    AkzoNobel Shareholders Approve Final Dividend at Annual General Meeting
    PPG Maintains EcoVadis Gold Rating
    Sustainable Plastics Will Make Up More Than 15% of Production by 2030
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Getinge Receives FDA Clearance for Multiple Products
    Study Shows Benefits of CCHD Screening Using Masimo SET Pulse Oximetry
    TEAM Technologies Acquires ViruDefense
    Contract Pharma

    Latest Breaking News From Contract Pharma

    RDIF, Minapharm to Make Over 40M Doses of the Sputnik V Vaccine in Egypt
    Bora Pharmaceuticals Completes Health Canada Inspection
    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Knoll Printing & Packaging Commits to a Healthy Ocean and Planet
    New Sustainable Jar from APC Packaging
    Qosmedix Launches Corporate Social Responsibility Initiative
    Happi

    Latest Breaking News From Happi

    Multi-Purpose Sustainable 'Just Add Water' Household Cleaner Expands Cleaning Products
    Kao Launches Oribe in Japan
    Love Beauty and Planet Shares Sustainability Initiatives With Refillable Hair Care at Target
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    SE-DA Invests in Kornit Presto S
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Epson upgrades SurePress demo facility
    Xeikon helps converters navigate toner and inkjet
    Mactac introduces Simply Sustainable initiative
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Savaré Strengthens Technical Support for the Americas
    FiberVisions, Avgol Partner with Polymateria
    High-Tech Conversions Launches Wipes Dispenser
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Clears Orthofix's 3D-Printed FORZA Titanium TLIF Spacer System
    Patients Conclude Clinical Visits in Knee Osteoarthritis Treatment Study
    SeaSpine Begins Limited Rollout of WaveForm TO 3D-Printed Interbodies
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Identiv, Ameta International Announce US, Canadian Distribution Partnership
    Adesis Achieves ISO 9001:2015 Certification
    Louis Widmer SA Complies with EU Anti-Counterfeiting Directive with Zebra Technologies’ Solution

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login